Pharmaceutical company AbbVie (NYSE: ABBV) met Wall Street’s revenue expectations in Q3 2026, with sales up 10.3% year on year to $17.4 billion. Its non-GAAP profit of $3.82 per share was 1.3% above analysts’ consensus estimates.

Is now the time to buy ABBV? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

AbbVie’s third quarter was marked by a positive market reaction, attributed to robust sales growth across its immunology and neuroscience portfolios. Management highlighted the continued momentum of key products like SKYRIZI, RINVOQ, and VRAYLAR, each delivering double-digit revenue increases. CEO Rob Michael emphasized that “nine key products delivered double-digit growth,” with particular strength in immunology and progress in new indications for neuroscience therapies. The quarter’s performance also benefited from newly approved treatments and advancements in product delivery, reflecting strong commercial execution.

Looking forward, AbbVie’s outlook is shaped by anticipated launches, expanding indications, and ongoing pipeline development. Management expects the recent subcutaneous induction approval for SKYRIZI in Crohn’s disease and upcoming launches for RINVOQ in vitiligo and alopecia areata to contribute meaningfully to future growth. CFO Scott Reents indicated that new product launches and continued uptake in neuroscience, including the Parkinson’s therapy JUVMO, will help sustain momentum. Management also sees opportunities in advancing combination therapies and new developments in oncology and obesity.

Key insights from management’s remarks

Management attributed the quarter’s performance to volume gains in immunology and neuroscience, product lifecycle expansion, and execution on new launches.

• Immunology volume expansion: SKYRIZI and RINVOQ both saw strong growth across indications, with SKYRIZI prescription trends holding up despite new competition. The subcutaneous induction approval in Crohn’s disease is expected to further strengthen SKYRIZI’s position and accelerate new patient share in coming quarters.

• Neuroscience product momentum: The company’s neuroscience segment was driven by VRAYLAR, UBRELVY, Qulipta, and the recent launch of JUVMO for Parkinson’s disease. Management noted that JUVMO, with its differentiated profile, is expected to gradually ramp up as commercial and Medicare coverage expands.

• Oncology pipeline progress: AbbVie highlighted positive developments in multiple myeloma (etentamig) and large B-cell lymphoma (Epkinly), with regulatory submissions underway and approvals anticipated next year. Management described these assets as underappreciated by the market and important contributors for future revenue.

• Aesthetics stabilization: While overall aesthetics sales declined slightly, BOTOX Cosmetic revenues grew modestly. Management observed early signs of stabilization in the aesthetics segment and is rolling out Boey, a new fast-acting toxin, in Europe and Canada.

• Strategic M&A and pipeline investments: The acquisition of Apogee Therapeutics added differentiated assets in dermatology and respiratory diseases, while business development remains focused on augmenting depth in core therapeutic areas rather than pursuing large-scale deals.

Drivers of future performance

AbbVie’s guidance centers on continued growth in immunology and neuroscience, new indication launches, and execution of its advancing pipeline strategy.

• New indication launches: Management expects the launch of SKYRIZI subcutaneous induction in Crohn’s disease and U.S. launches of RINVOQ in vitiligo and alopecia areata to drive further growth. These new indications are anticipated to expand the addressable patient base and reinforce market share in key therapeutic areas.

• Pipeline milestones and regulatory events: Anticipated approvals for etentamig in multiple myeloma and Epkinly in large B-cell lymphoma are seen as major near-term catalysts. Additionally, positive interim data from various late-stage trials, particularly in immunology and neuroscience, could accelerate future launches and revenue streams.

• Market access and payer dynamics: Management identified strong payer access for new launches as a key to sustaining growth, with low single-digit rebate concessions expected. However, external factors such as regulatory changes, competitive pressures, and evolving reimbursement frameworks present ongoing risks.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will monitor (1) the adoption and uptake of new indications for SKYRIZI and RINVOQ, (2) regulatory progress and potential approvals for key oncology and neuroscience assets, and (3) stabilization trends in the aesthetics portfolio, particularly the rollout of Boey. Additional late-stage clinical trial data and results from combination therapies in immunology will also be important markers of success.

AbbVie currently trades at $294.17, in line with $291.46 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.